MedTrace Logo

Ketorolac in Breast Cancer Surgery

NCT01806259 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2020-04-07

Study results available
· View outcomes & findings →

Summary

Do the use of Ketorolac in one intravenous injection at the moment of the operative incision reduce the number of recurrence in patient with advanced breast cancer without inflammation signs.

Conditions

  • Curative Breast Cancer Surgery
  • Inflammatory Positive/Negative Status
  • Pre Surgical Incision Administration

Interventions

DRUG

Ketorolac 30 mg IV

Active drug

DRUG

Placebos

Placebo looking like the Active drug

Sponsors & Collaborators

  • Anticancer Fund, Belgium

    collaborator OTHER

  • Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Patrice Forget, MD · Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-10-31
Completion
2018-09-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01806259 on ClinicalTrials.gov